Ipsen reports positive growth in first half of 2012

Ipsen has voiced its satisfaction with its first-half performance for 2012 after demonstrating robust year-over-year growth.

The company generated 675 million euros (535.78 million pounds) during the six-month period, up by nine percent annually, while drug sales improved by 6.3 percent compared to the first half of 2011.

Ipsen experienced strong growth in its specialty care operations, which helped to offset challenging conditions for its primary care division, while it has also been able to raise its sales objectives for the full year.

Moreover, the company is also making progress on nine phase III clinical trials and recently renegotiated its strategically important haemophilia partnership with Inspiration Biopharmaceuticals.

The two businesses are still looking to create a joint haemophilia business unit to handle all products in this field commercialised under the Inspiration brand in Europe.

Marc de Garidel, chairman and chief executive officer of Ipsen, said: "Ipsen has once again illustrated the pertinence of focusing on specialty therapeutic areas. Each of the group's three specialty care franchises showed double-digit growth over the period."